潮汕兄弟卖减肥药，2个月飚涨20亿元

Group 1 - Hanyu Pharmaceutical announced a partnership with cryptocurrency exchange KuCoin to tokenize intangible assets related to innovative drugs, which significantly boosted its stock price and market capitalization to approximately 21.5 billion yuan by August 11 [2] - The company reported a net profit of over 140 million yuan for the first half of 2023, driven by a major contract for a weight-loss drug in the U.S. [3] - Hanyu Pharmaceutical is set to become the first company to produce a generic version of liraglutide injection approved by the U.S. FDA by the end of 2024, which will aid in blood sugar management for relevant populations [3] Group 2 - The three controlling brothers of Hanyu Pharmaceutical, from Guangdong, hold a combined 20.76% stake in the company, resulting in an increase of 2 billion yuan in their wealth over the past two months [5]